NASDAQ: KTTA
Pasithea Therapeutics Corp Stock Ownership - Who owns Pasithea Therapeutics?

Insider buying vs selling

Have Pasithea Therapeutics Corp insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Alfred J. NovakDirector2024-06-132,750$5.62
$15.46kBuy
Alfred J. NovakDirector2024-06-12750$5.61
$4.21kBuy

1 of 1

KTTA insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when KTTA insiders and whales buy or sell their stock.

KTTA Shareholders

What type of owners hold Pasithea Therapeutics Corp stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Pd Joint Holdings LLC Series 2016a96.43%2,608,696$3.60MInsider
Eric Shahinian66.11%1,788,415$2.47MInsider
Lawrence Steinman47.40%1,282,174$1.77MInsider
Israel Maxx Abramowitz38.87%1,051,575$1.45MInsider
Avi Geller38.25%1,034,702$1.43MInsider
Dean Lazer33.36%902,600$1.25MInsider
Eric Lazer33.36%902,600$1.25MInsider
Tiago Marques30.28%819,206$1.13MInsider
Yassine Bendiabdallah11.09%300,000$414.00kInsider
David Delaney8.41%227,521$313.98kInsider

1 of 2

KTTA vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
KTTA0.70%99.30%Net Buying
WINT0.33%99.67%Net Buying
DRMA0.84%85.19%
OGEN0.59%99.41%Net Selling
JAGX2.83%97.17%

Pasithea Therapeutics Stock Ownership FAQ

Who owns Pasithea Therapeutics?

Pasithea Therapeutics (NASDAQ: KTTA) is owned by 2.85% institutional shareholders, 405.54% Pasithea Therapeutics insiders, and 0.00% retail investors. Pd Joint Holdings LLC Series 2016a is the largest individual Pasithea Therapeutics shareholder, owning 2.61M shares representing 96.43% of the company. Pd Joint Holdings LLC Series 2016a's Pasithea Therapeutics shares are currently valued at $3.73M.

If you're new to stock investing, here's how to buy Pasithea Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.